People usually search for this
Epithalon 50mg
$160.00
≥99% purity · HPLC verified · MS confirmed
How we test →
Products will arrive in a lyophilized (powder) form for maximum stability
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation and Gerontology, studied primarily in Russian research for telomerase activation, pineal gland function, and longevity endpoints. Western replication of these findings remains limited. Supplied as a 50mg lyophilized vial at ≥99% HPLC purity, for research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
Epithalon
SYNONYMS
Ala-Glu-Asp-Gly; epithalone; pineal peptide tetrapeptide
CAS NUMBER
307297-39-8
MOLECULAR FORMULA
C14H22N4O9
MOLECULAR WEIGHT
~390.35 g/mol
STRUCTURE
Synthetic tetrapeptide
PEPTIDE SEQUENCE
H-Ala-Glu-Asp-Gly-OH
CHEMICAL STRUCTURE
Molecular Formula: C14H22N4O9
Source: PubChem
Mechanism of Action
Epithalon functions by upregulating telomerase reverse tranceiptase (TERT) activity in somatic cells, which promotes telomere elongation and chromosomal stability. It also suppresses expression of certain oncogenes such as HER-2/neu, contributing to its antitumor effects. Additionally, Epithalon reduces oxidative stress and restores circadian melatonin secretion rhythms in aged animals2,3.
1
Activation of Telomerase Reverse Transcriptase (TERT)
2
Downregulation of HER-2/neu Expression
Biological Activity
Epithalon has been shown to increase lifespan in rodent models, reduce spontaneous and induced tumor formation, stabilize the genome by reducing chromosomal aberrations, and modulate immune cell proliferation. Its actions extend to radioprotective effects on the thymus and intestinal mucosa1,4.
Storage
- −20°C or below. Protect from light and moisture.
Drug Categories
Peptides; Bioregulators; Geroprotective Compounds
Additional Notes
- Originally synthesized at the St. Petersburg Institute of Bioregulation and Gerontology.
- Noted for unique pineal gland regulatory function and epigenetic modulation potential.
- Epithalon is a research-use-only compound. It is not FDA-approved and has not completed full clinical trials. It is supplied for laboratory investigation only and is not intended for diagnostic or therapeutic use in humans.
Summary Table
Property
Description
CAS Number
307297-39-8
Molecular Formula
C14H22N4O9
Molecular Weight (MW)
~390.35 g/mol
Mechanism of Action
TERT activation, HER-2/neu suppression
Biological Activity
Antioxidant, antitumor, geroprotective
Supplied Form
Lyophilized powder
Purity
≥95% (HPLC)
Storage
–20°C lyophilized, –80°C reconstituted
Drug Categories
Peptides, Bioregulators, Geroprotectives
Additional Notes
Derived from pineal peptide epithalamin
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
Epithalon is a stabilized synthetic tetrapeptide analogue of the endogenous pineal peptide epithalamin. It was developed to replicate and enhance the biological functions of pineal-derived factors that regulate aging and genome integrity. Preclinical studies have demonstrated that Epithalon activates telomerase in somatic cells through activation of telomerase reverse transcriptase, which promotes telomere elongation, and delays cellular senescence. These mechanisms are believed to underpin its geroprotective effects1. Epithalon has been extensively evaluated in aging-prone and cancer-prone rodent models, where it has been shown to reduce spontaneous tumor formation, suppress oncogene expression (notably HER-2/neu), and increase median and maximal lifespan1,2. The peptide also restores melatonin secretion rhythms in aged animals and stabilizes genomic integrity by reducing age-associated chromosomal aberrations. While not approved for human use, epithalon is actively used in laboratory research on aging, cancer biology, and radioprotection. It is intended solely for investigational applications involving cellular senescence, telomerase modulation, and epigenetic reprogramming in experimental models of aging and age-related disease3,4.
Research Highlights
Lifespan Extension:
Increased lifespan in CBA and SAMP-1 mice compared to controls1.
Antitumor Effects:
Reduced spontaneous and induced tumor growth in multiple murine models4.
HER-2/neu Suppression:
Decreased oncogene expression and tumor burden in transgenic mice4.
Radioprotection:
Promotes regeneration in radiosensitive organs post-irradiation (e.g., thymus, spleen).
Genomic Stability:
Lower incidence of chromosomal mutations in aging models3.
Circadian Regulation:
Restores melatonin rhythmicity in aged animals1.
Epithalon induces the expression and activity of telomerase reverse transcriptase in somatic cells, promoting elongation of telomeric DNA repeats at chromosomal termini. Telomere attrition is a hallmark of replicative senescence and genomic instability, particularly in highly mitotic tissues4. By sustaining telomere integrity, Epithalon enhances proliferative capacity, reduces the incidence of chromosomal aberrations, and preserves nuclear genomic architecture in aging cells. In senescence-accelerated murine models, TERT activation by Epithalon correlates with increased median and maximal lifespan, reduced incidence of cytogenetic anomalies in bone marrow metaphases, and improved resistance to oxidative and genotoxic stress2,4.
In transgenic FVB/N mice overexpressing the human HER-2/neu (erbB-2) oncogene, Epithalon administration results in a significant reduction in HER-2/neu mRNA levels, with a reported 3.7-fold decrease relative to saline controls. HER-2/neu encodes a receptor tyrosine kinase involved in mitogenic signaling via the MAPK and PI3K/AKT pathways and is implicated in the pathogenesis of multiple epithelial malignancies, including breast carcinoma. Epithalon’s suppression of HER-2/neu expression is associated with delayed tumor onset, reduced tumor multiplicity, and decreased tumor volume. These data suggest a transcriptional regulatory mechanism through which Epithalon modulates oncogenic signaling and suppresses neoplastic progression in HER-2-driven tumorigenesis4.
Pharmacokinetic Profile
Route of Administration
Subcutaneous
Dosing Frequency
Once daily
- Route of Administration: Subcutaneous injection
- Dosing Frequency: Once daily
- Half-Life: Not formally established in humans; estimated short plasma half-life typical of small peptides (minutes to low hours)2.
- Formulation: Lyophilized powder for reconstitution
Formulation & Handling
- Lyophilized peptide powder, reconstituted in sterile PBS or water.
- Store lyophilized peptide at –20?°C; upon reconstitution, aliquot and freeze at –80?°C to avoid degradation.
- Avoid repeated freeze–thaw cycles.
Selected Clinical Trial Activity
Epithalon is a research-grade compound that has been studied in laboratory settings but has not undergone full clinical development. It is not approved for therapeutic use in humans, and no large-scale clinical trials have been conducted to evaluate its safety or efficacy as a medication. Epithalon is supplied strictly for laboratory research and investigational purposes only.
References
1
Anisimov, V. N., Khavinson, V. Kh., Alimova, I. N., Provintsiali, M., Manchini, R., & Francheski, K. Epithalon inhibits tumor growth and expression of HER-2/neu oncogene in breast tumors in transgenic mice characterized by accelerated aging. Bull Exp Biol Med. 133, 167–170 (2002).
2
Rosenfeld, S.V. et al. Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice. Bull Exp Biol Med. 133, 274–276 (2002)
3
Khavinson, V.K. et al. Immunohistochemical and morphometric analysis of effects of vilon and epithalon on functional morphology of radiosensitive organs. Bull Exp Biol Med. 131, 285–292 (2001).
4
Anisimov, V.N. et al. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic HER-2/neu mice. Bull Exp Biol Med. 134, 187–190 (2002).
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart Related products
BPC-157 5mg
Summary Description: BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a protein found in human gastric juice. In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties1-3. BPC-157 accelerates tissue repair across tendon, ligament, muscle, and epithelial models by modulating nitric oxide pathways, upregulating VEGF and other growth factors, and promoting fibroblast migration4. Its chemical stability in gastric environments and efficacy across multiple administration routes make it a candidate for further investigation in regenerative pharmacology2.
Products will arrive in a lyophilized (powder) form for maximum stability
BPC-157/TB-500 10+10mg
Summary Description: BPC-157 and TB-500 is an investigational blend of two well-studied peptides known for their regenerative and cytoprotective properties. BPC-157, derived from a gastric protein, is recognized for promoting angiogenesis, cellular migration, and tissue healing across various organ systems1,2. TB-500, a synthetic fragment of thymosin beta-4, enhances cellular motility, reduces inflammation, and stimulates new blood vessel formation3,4. Together, this synergistic blend is being explored in preclinical research for its ability to accelerate wound healing, mitigate inflammation, and enhance recovery in models of soft tissue injury, nerve damage, and musculoskeletal trauma. While individually effective, the co-administration of BPC-157 and TB-500 may produce more robust regenerative outcomes by targeting both the structural and signaling components of tissue repair.
Products will arrive in a lyophilized (powder) form for maximum stability
CJC-1295 (No DAC)/Ipamorelin Blend 5+5mg
Summary Description: The CJC-1295 (no DAC) + Ipamorelin peptide blend merges two potent growth hormone secretagogues to synergistically enhance physiologic GH pulsatility. This research-only combination stimulates both GHRH and ghrelin receptor pathways, yielding amplified and sustained GH release while maintaining endocrine feedback sensitivity.
Products will arrive in a lyophilized (powder) form for maximum stability
IGF-1 LR3 1mg
Summary Description: IGF1-LR3 (Long R3 Insulin-like Growth Factor 1) is a recombinant peptide analog of human IGF-1 designed for enhanced bioavailability and potency. Unlike native IGF-1, this analog features a 13-amino acid N-terminal extension and an arginine substitution at position 3, conferring reduced affinity for insulin-like growth factor binding proteins (IGFBPs) and thus increased biological activity across multiple experimental models. IGF1-LR3 is widely used to investigate anabolic, anti-catabolic, and cell survival pathways in both in vivo and in vitro research settings1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
PT-141 10mg
Summary Description: PT-141 is a synthetic cyclic heptapeptide derivative of alpha-melanocyte stimulating hormone (?-MSH), designed to act as a potent and selective melanocortin receptor agonist, particularly at MC3 and MC4. It is primarily researched for its unique ability to induce sexual arousal and enhance sexual function in both men and women without acting via direct hormonal or vascular mechanisms. PT-141 is supplied strictly for laboratory research use1,2,4.
Products will arrive in a lyophilized (powder) form for maximum stability
SS-31 50mg
Summary Description: SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that binds selectively to cardiolipin in the inner mitochondrial membrane. It acts as a mitochondrial protective agent, stabilizing mitochondrial structure, enhancing oxidative phosphorylation, reducing production of reactive oxygen species (ROS), and mitigating cellular damage in diverse models of mitochondrial dysfunction. Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction1-6.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 10mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Tirzepatide 10mg
Summary Description: Tirzepatide is a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for the treatment of type 2 diabetes and obesity. Engineered as a synthetic peptide based on the native GIP sequence and modified for extended half-life via fatty acid conjugation, tirzepatide delivers glycemic control, profound weight loss, and cardiometabolic benefits. Its imbalanced receptor affinity and biased signaling provide enhanced insulin secretion and improved metabolic outcomes beyond selective GLP-1 agonism.1,3,4
Products will arrive in a lyophilized (powder) form for maximum stability